KY-1702

N/A

Report date: 2025/02/26 15:15:32
NME

Base Information

Drug NameKY-1702
Drug Alias NameKY1702KY-1702
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Kanion Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Kanion Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A